NEW YORK (GenomeWeb News) – Foundation Medicine's supply, service, and support agreement with Illumina inked in July is for five years and approximately $6.1 million, the Cambridge, Mass.-based firm said in an amended Form S-1 filed this week. The company originally disclosed the deal with Illumina in its Form S-1 filed in July in preparation of its initial public offering, but did not reveal the terms. Foundation plans to offer up to $86.3 million in its IPO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.